Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer
Public ClinicalTrials.gov record NCT03349710. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin
Study identification
- NCT ID
- NCT03349710
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Cetuximab Drug
- Cisplatin Drug
- Radiotherapy Radiation
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2017
- Primary completion
- Oct 13, 2019
- Completion
- Oct 13, 2019
- Last update posted
- Aug 8, 2021
2017 – 2019
United States locations
- U.S. sites
- 21
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pinnacle Research Group, Llc | Anniston | Alabama | 36207 | — |
| Cancer Treatment Centers of Phoneix | Goodyear | Arizona | 85338 | — |
| University of Arizona Cancer Center | Tucson | Arizona | 85724-5024 | — |
| UCLA Health | Los Angeles | California | 90095 | — |
| Cancer Care - Torrance Memorial Physician Network | Redondo Beach | California | 90277 | — |
| Cancer Center of Central Connecticut | Plainville | Connecticut | 06062 | — |
| Orlando Health, Inc | Orlando | Florida | 32806 | — |
| Winship Cancer Insitute, Emory Crawford Long Hospital | Atlanta | Georgia | 30308 | — |
| CTCA Southeastern Region | Newnan | Georgia | 30265 | — |
| Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital | Thomasville | Georgia | 31792 | — |
| Midwestern Regional medical Center | Zion | Illinois | 60099 | — |
| Fort Wayne Medical Oncology and Hematology, Inc. | Fort Wayne | Indiana | 46845 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114-4108 | — |
| Monter Cancer Center - Center for Advanced Medicine Location | Lake Success | New York | 11042 | — |
| Eastern Regional Medical Center | Philadelphia | Pennsylvania | 19124 | — |
| Upmc- Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| St. Joseph Regional Cancer Center | Bryan | Texas | 77802-2585 | — |
| The University of Texas MD Anderson Cancer Center-merge | Houston | Texas | 77030 | — |
| Inova Health System | Falls Church | Virginia | 22042 | — |
| HHP Hematology & Oncology Bremerton | Bremerton | Washington | 98310 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03349710, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 8, 2021 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03349710 live on ClinicalTrials.gov.